Market news

Tipranks Press Release.

RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment

Mesoblast (NASDAQ:MESO) reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company’s FDA-approved allogeneic mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, or GVHD. Chief Executive Of

Tipranks Press Release.

NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the...

Detailed price information for Mesoblast Ltd ADR (MESO-Q) from The Globe and Mail including charting and trades.

Mesoblast Limited (NASDAQ:MESO) shares rose 9. 5% on Monday after the biotechnology company completed patient treatment in a pivotal Phase 3 study evaluating rexlemestrocel-L for chronic low back pain linked to degenerative disc disease.

Detailed price information for Cullinan Therapeutics Inc (CGEM-Q) from The Globe and Mail including charting and trades.

Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases

Detailed price information for Mesoblast Ltd ADR (MESO-Q) from The Globe and Mail including charting and trades.